AI English summary of an SEC filing — figures as filed
West Pharmaceutical Services WSTWest Pharmaceutical Services said consolidated net sales for the 3-month period ended September 30, 2024 decreased $0.5 million (0.1%) from the same period a year earlier. Excluding foreign currency translation effects, net sales decreased $3.4 million (0.5%).
Key points
AI summaryWest Pharmaceutical Services said consolidated net sales for the 3-month period ended September 30, 2024 decreased $0.5 million (0.1%) from the same period a year earlier. Excluding foreign currency translation effects, net sales decreased $3.4 million (0.5%).
The company said consolidated gross profit for the 3-month period decreased $23.6 million (8.2%) and gross profit margin fell 3.2 margin points. The company cited a shift in sales mix from HVP Components to HVP Delivery Devices and lower plant absorption as factors behind the decline in Proprietary Products margin.
The company said consolidated operating profit for the 3-month period decreased $16.0 million (9.0%). Income tax expense was $32.4 million, with an effective tax rate of 19.7%, up from $29.4 million (15.7%) a year earlier.
West Pharmaceutical Services said as of September 30, 2024, $80.3 million of its cash and cash equivalents was held by U.S. subsidiaries and $410.6 million was held by subsidiaries outside the U.S. It also said it repurchased 1,409,786 shares for $506.5 million over 9 months. The company also said it had no borrowings outstanding under its multi-currency revolving credit facility on the same date.
Key figures
Quarter ended September 30, 2024
- Revenue
- $747M
- Operating income
- $161M
- Net income
- $136M
- EPS
- $1.85
- Gross profit
- $265M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Quarterly Consolidated Net Sales Edge Down
West Pharmaceutical Services said consolidated net sales for the 3-month period ended September 30, 2024 decreased $0.5 million (0.1%) from the same period a year earlier. Excluding foreign currency translation effects, net sales decreased $3.4 million (0.5%).
Source · Based on the MD&A text of the filing
Quarterly Gross Profit Decline and Segment Commentary
The company said consolidated gross profit for the 3-month period decreased $23.6 million (8.2%) and gross profit margin fell 3.2 margin points. The company cited a shift in sales mix from HVP Components to HVP Delivery Devices and lower plant absorption as factors behind the decline in Proprietary Products margin.
Source · Based on the MD&A text of the filing
Quarterly Operating Profit and Effective Tax Rate
The company said consolidated operating profit for the 3-month period decreased $16.0 million (9.0%). Income tax expense was $32.4 million, with an effective tax rate of 19.7%, up from $29.4 million (15.7%) a year earlier.
Source · Based on the MD&A text of the filing
9-Month Share Repurchases and Liquidity
West Pharmaceutical Services said as of September 30, 2024, $80.3 million of its cash and cash equivalents was held by U.S. subsidiaries and $410.6 million was held by subsidiaries outside the U.S. It also said it repurchased 1,409,786 shares for $506.5 million over 9 months. The company also said it had no borrowings outstanding under its multi-currency revolving credit facility on the same date.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…